




PHARMACEUTICAL 2019

Karyopharm Therapeutics Inc.
Rank 215 of 363





RealRate

PHARMACEUTICAL 2019

Karyopharm Therapeutics Inc. Rank 215 of 363



The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 18% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	334,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,904
Liabilities, Non-Current	0
Other Assets	2,717
Other Compr. Net Income	-27
Other Expenses	26
Other Liabilities	111,118
Other Net Income	1,502
Other Revenues	30,336
Property and Equipment	3,863
Research and Development	161,372
Selling, General and Administrative Expense	48,847

Output Variable	Value in 1000 USD
Assets	341,192
Liabilities	158,022
Expenses	210,245
Revenues	30,336
Stockholders Equity	183,170
Net Income	-178,407
Comprehensive Net Income	-178,420
Economic Capital Ratio	55%